AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Shionogi & Co., Ltd.
Video analysis: SGIOY
All videosNo video analysis for this stock yet. Request one from our team.
News: SGIOY
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C. Data highlights at IDWeek 2026 include an oral presentation featuring a subpopulation analysis from the global Phase 3 SCORPIO-PEP trial, a rapid-fire session focused on ventilator-ass.
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-trea.
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.18 per share.
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Similar companies
-
Olympus Corporation
OCPNF
·
Other OTC
Compare
-
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF
·
Other OTC
Compare
-
Swedish Orphan Biovitrum AB (publ)
BIOVF
·
Other OTC
Compare
-
CSPC Pharmaceutical Group Limited
CHJTF
·
Other OTC
Compare
-
bioMérieux S.A.
BMXMF
·
Other OTC
Compare
-
Alibaba Health Information Technology Limited
ALBHF
·
Other OTC
Compare